CytoDyn Enters into Research Funding and Option Agreement With The Scripps Research Institute

LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the “Company”) (OTC:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a Research Funding and Option Agreement (the “Agreement”) with The Scripps Research Institute (“Scripps Research”), a nonprofit institution, that will enable Dr. John H. Elder, Professor in the Department of Immunology and Microbial Science at Scripps Research, to explore the potential application of the Company’s recently provisionally patented technology (which the Company has applied to trademark as CytoFeline) as an effective therapy in the treatment of feline immunodeficiency virus (“FIV”). Dr. Elder is a leading FIV researcher, having researched and published his findings on FIV for more than 20 years. The Company has assigned the Agreement to its wholly owned subsidiary, CytoDyn Veterinary Medicine LLC.